/Investor DB

SV Health Investors — 2026 Investments

6 investments dated 2026 · listed companies and verified rows first · show all

Pulse BiosciencesNASDAQ: PLSEMay 2026 · $13M

Pulse Biosciences develops and commercializes ablation systems based on nanosecond pulsed-field ablation technology to treat medical conditions including benign skin lesions, soft tissue tumors, and cardiac arrhythmias.

BiotechBurlingame, US

Brian B. Dow(Executive Officer)Darrin R. Uecker(Executive Officer, Director)Amy Wang(Executive Officer, Director)Paul A. LaViolette(President and Chief Executive Officer)

BoardMaky Zanganeh(Director)Christopher Marlett(Director)

Mestagmestagtherapeutics.comin𝕏Mar 2026 · $40M✓ verified

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)Mark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)Lindsey Rolfe(Chief Medical Officer)in

Co-investorsGV (Google Ventures)ForbionJohnson & Johnson Innovation – JJDCNorthpond VenturesJJDC

Csa Medical Increjuvenair.cominSeries B · Jun 2026 · $21M

RejuvenAir, developed by CSA Medical, is a bronchoscopic cryosurgical device that sprays metered doses of liquid nitrogen to destroy damaged airway cells and treat the underlying cause of COPD with Chronic Bronchitis.

HealthtechMedical DevicesLutherville, US

Ellen Sheets(Executive Officer, Director)inIan J. Vawter(Executive Officer)Steven Schaefer(Executive Officer)inWilliam Floyd(Executive Officer, Director)inVincent Owens(Director)Richard Kent(Director)

Board seatPaul LaViolette· per SEC Form D

Co-investorsAscension VenturesFirst AnalysisNew Markets Venture PartnersBlue Heron CapitalTVM CapitalTVM Capital Life Science

AdvanCell Isotopesadvancell.com.auinSeries C · Jun 2026 · $110M

AdvanCell is a clinical-stage radiopharmaceutical company developing a pipeline of targeted alpha therapies for the treatment of cancers including prostate, melanoma, ovarian, breast, and lung.

BiotechHealthtechMedical DevicesCambridge, US

Andrew Adamovich(Director)inPhilina Lee(Executive Officer, Director)inAaron Pickett(Executive Officer)in

BoardWing Cheong Lam(Director)Nik Economopoulos(Director)Anthony Aiudi(Director)

Co-investorsBain Capital Life SciencesCatalio Capital Management, LPProto AxiomSanofi VenturesTenmileAbingworth+2 more

MSTmst-sys.comMar 2026 · $40M

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAgate Medical Investments LPSCP Vitalife PartnersForbionGV (Google Ventures)Northpond Ventures

Paymedixpaymedix.cominJan 2026 · $16M

PayMedix simplifies healthcare payments by paying providers in full for allowed in-network claims and streamlining patient billing, improving access to care regardless of financial status.

Digital HealthEnterprise SoftwareFintechHealthtech

Tom Policelli(Chief Executive Officer)inBrian Marsella(President)in

Co-investorsHLM Investment Partners

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.